Search CCCC
C4 Therapeutics, Inc.
Nasdaq · CIK 1662579
Last close2.95
Daily change-0.19 (-6.05%)
10 Years gain-88.43%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CCCC · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
32.3Momentum
0.0Acceleration
18.5Confidence
80.0Annual Revenue5
Quarterly Revenue16
Annual CFO7
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth3.8 / 25
Quality8.6 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators4.9 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 89.1365 percentage points.
Heavy share dilution · HIGHDiluted share count increased 84.5138%.
Key Metrics
Revenue Growth TTM-19.02%OK
Revenue CAGR 3Y4.95%OK
Gross Margin100%OK
Operating Margin-384.18%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-50.87%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y84.51%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $35.95M | $35.95M | -$115.22M | -$98.69M | -$99.30M | 100% | -320.53% | -276.24% | -53.16% | 82.89M |
| 2025 FY Dec 31, 2024 | $35.58M | $35.58M | -$119.61M | -$65.16M | -$65.34M | 100% | -336.15% | -183.61% | -67.49% | 69.37M |
| 2024 FY Dec 31, 2023 | $20.76M | $20.76M | -$139.03M | -$106.84M | -$108.55M | 100% | -669.84% | -522.96% | -56.26% | 49.64M |
| 2023 FY Dec 31, 2022 | $31.10M | $31.10M | -$129.53M | -$105.94M | -$111.44M | 100% | -416.56% | -358.36% | -56.53% | 48.86M |
| 2022 FY Dec 31, 2021 | $45.79M | $45.79M | -$82.13M | -$86.97M | -$88.24M | 100% | -179.39% | -192.73% | -1,266.19% | 46.04M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $30.49M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-055494, 0001628280-25-049854 |
| Revenue Growth TTM | -19.02% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-055494, 0001628280-25-049854 |
| Revenue CAGR 3Y | 4.95% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-012000 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001628280-26-012000 |
| Gross Profit CAGR 3Y | 4.95% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-012000 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-055494, 0001628280-25-049854 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001628280-26-055494, 0001628280-25-049854 |
| Operating Margin | -384.18% | Operating Income / Revenue | OK | 0001628280-26-055494, 0001628280-25-049854 |
| ROIC | -50.87% | NOPAT / Average Invested Capital | OK | 0001628280-26-055494, 0001628280-25-049854 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-055494 |
| Current Ratio | 5.45x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.23 | Revenue / Diluted Shares | OK | 0001628280-26-055494, 0001628280-25-049854 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |